Ambrx (NYSE: AMAM) has initiated a Phase 1 trial for ARX517, an anti-PSMA antibody drug conjugate, targeting tumors expressing prostate-specific membrane antigen. The trial aims to evaluate safety, pharmacokinetics, and anti-tumor activity in up to 76 patients with advanced solid tumors. Preclinical results indicate strong potential efficacy against both enzalutamide-sensitive and resistant prostate cancer. The global prostate cancer therapy market, valued at $9.3 billion in 2018, is projected to grow significantly, highlighting the opportunity for ARX517's success.
Ambrx (NYSE: AMAM) has appointed Sonja Nelson as Chief Financial Officer, enhancing its executive team amid ongoing expansion. Nelson, with over 10 years of executive experience in biotechnology, previously served at NantKwest and AltheaDx. Dr. Feng Tian, Chairman and CEO, expressed confidence in her ability to guide Ambrx's financial strategy as the company advances its development pipeline, including the lead candidate ARX788. Ambrx utilizes an expanded genetic code technology platform aimed at creating innovative biologics across various therapeutic areas.
Ambrx, a clinical stage biopharmaceutical company, has priced its initial public offering (IPO) at $18.00 per American depositary share (ADS), raising $126.0 million before expenses. The offering includes 7,000,000 ADSs, with an additional 1,050,000 ADSs available for underwriters. Trading on the New York Stock Exchange under the ticker symbol AMAM is set to begin on June 18, 2021, with closing expected on June 22, 2021. Notably, Ambrx focuses on developing Engineered Precision Biologics, including innovative therapies for various diseases.